logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12594321 B1

PDFFull Text
Date of Patent:
Apr. 07, 2026

Filed:

Dec. 05, 2023

Bispecific chimeric antigen receptor that binds cd19 and cd20, encoding nucleic acid molecules thereof and methods of use thereof to treat cancer

Applicants:

Novartis Ag, Basel, CH;

The Trustees of the University of Pennsylvania, Philadelphia, PA (US);

Inventors:

Barbara Brannetti, Cambridge, MA (US);

Jennifer Brogdon, Sudbury, MA (US);

Boris Engels, Arlington, MA (US);

Brian Walter Granda, Salisbury, MA (US);

Ming Lei, Acton, MA (US);

Jimin Zhang, Chestnut Hill, MA (US);

Assignees:

Novartis AG, Basel, CH;

The Trustees of the University of Pennsylvania, Philadelphia, PA (US);

Attorney:

K&L Gates LLP

Primary Examiner:

Robert S Landsman

Int. Cl.
CPC ...
A61K 38/17 (2006.01); A61K 39/00 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01); C12N 15/85 (2006.01);
U.S. Cl.
CPC ...
A61K 38/1774 (2013.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4211 (2025.01); A61K 40/4212 (2025.01); A61K 40/4221 (2025.01); A61P 35/00 (2018.01); C07K 16/2803 (2013.01); C07K 16/2887 (2013.01); C07K 16/2896 (2013.01); C12N 5/0636 (2013.01); C12N 15/85 (2013.01); A61K 2039/505 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01);
Abstract

The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.

Find Patent Forward Citations

Brannetti, Barbara. (2026). Bispecific chimeric antigen receptor that binds cd19 and cd20, encoding nucleic acid molecules thereof and methods of use thereof to treat cancer (U.S. Patent No. 12594321). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/12594321

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…